A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (Illuminate 101)
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs IMO 2125 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms ILLUMINATE 101
- Sponsors Idera Pharmaceuticals
- 07 Mar 2018 According to an Idera Pharmaceuticals media release, as of 7 Mar 2018, two subjects in cohort 1 (8 mg) continue IMO-2125 monotherapy.
- 07 Mar 2018 According to an Idera Pharmaceuticals media release, this trial has completed enrollment in first two cohorts (n=11 in cohort 1 and n=8 in cohort 2) and enrollment of third cohort has commenced.
- 05 Jan 2018 According to an Idera Pharmaceuticals media release, Completed enrollment in first cohort and andvanced enrollment in second cohort.